The combination of Nektar Therapeutics' investigational interleukin-2 (IL-2) agent NKTR-214 with Bristol-Myers Squibb Co.'s PD-1 inhibitor Opdivo has activity in lung, kidney cancer and melanoma, the partners said at the Society for Immunotherapy and Cancer meeting in November.
Nektar and Bristol presented positive early data for the combination of NKTR-214 and Opdivo in renal cell carcinoma, melanoma and...






